Key clinical point: Young-onset colorectal cancer has distinct clinical and molecular features versus older-onset disease.
Major finding: Patients under 50 years of age were more likely to have distal primary tumors, synchronous metastatic disease, and microsatellite instability (MSI), compared with older patients, and they were less likely to have BRAF V600 mutations.
Study details: Retrospective analysis including more than 36,000 patients with CRC.
Disclosures: Support came from the National Cancer Institute, National Institutes of Health, and the MD Anderson Colorectal Cancer Moon Shot Program. The senior investigator reported disclosures related to Roche, Genentech, EMD Serono, Merck, Karyopharm, Amal, Navire, Symphogen, Holystone, Biocartis, Amgen, and Novartis.
Willauer AN et al. Cancer. 2019 Mar 11. doi: 10.1002/cncr.31994.